Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.
Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.
Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.
Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.
The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.
The company did not declare any dividend for the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments